Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 TrialZhang, Jingjing, MD, PhD; Kulkarni, Harshad R., MD; Singh, Aviral, MD, MSc; Baum, Richard P., MD, PhDClinical Nuclear Medicine: March 2019 - Volume 44 - Issue 3 - p 223–226 doi: 10.1097/RLU.0000000000002456 Interesting Images Abstract Author InformationAuthors Article MetricsMetrics Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues has been shown to be highly efficacious concerning progression-free survival and response rates in patients with advanced, progressive, well-differentiated, somatostatin-receptor–positive neuroendocrine neoplasm. We report here delayed response of a midgut neuroendocrine neoplasm patient, who had stable disease after 4 cycles of PRRT and over a long period of 5 restaging admissions with excellent quality of life (full working hours), persisting for 3 years of follow-up, and presented as further partial remission according to both Response Evaluation Criteria in Solid Tumors and EORTC criteria, respectively, 36 months after the last PRRT cycle. From the Theranostics Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, Germany. Received for publication November 2, 2018; revision accepted November 27, 2018. Conflicts of interest and sources of funding: none declared. Correspondence to: Richard P. Baum, MD, PhD, Theranostics Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437 Bad Berka, Germany. E-mail: firstname.lastname@example.org. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.